These findings suggest that rotenone affects 5-HT and its receptor, GI motility factors, aquaporins and intestinal inflammation/barrier-related factors, likely via the PI3K/AKT pathway, highlighting its role in rotenone-induced constipation in PD. This evidence concerns the gene AKT1 and Parkinson disease.